Supreme Court Decided Not News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Supreme court decided not. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Supreme Court Decided Not Today - Breaking & Trending Today

Intellectual Property Bulletin - Winter 2021 | Fenwick & West LLP

Hayan Yoon
In two 2019 rulings
, the Federal Circuit invoked the “written description requirement” of 35 U.S.C. § 112 to require evidentiary support for therapeutic efficacy. Now that the Supreme Court has declined to hear one of those cases, “written description” will continue to present a hurdle to patentability, in addition to the utility and enablement requirements.
Litigation-Proofing Your Trade Secrets: Practical Steps to Ensure They’re Enforceable in Court
Robert Counihan and Jedediah Wakefield
Trade secret litigation is on the rise, and new case law related to enforceability has broad implications for how companies protect information that they consider to be trade secrets. Drawing on these cases, we offer practical steps for ensuring that your company’s trade secret “crown jewels” are enforceable in court especially if your business is in a knowledge-based sector, such as technology or life sciences. ....

United States , New York , Fenwick West , New Jersey , South Korea , South Korean , Halle Berry , Yan Li , Justice Barrett , Emily Ratajkowski , Eli Lilly , Lebron James , Khloe Kardashian , Robert Counihan , James Facebook , Justice Amy Coney Barrett , Gigi Hadid , Justin Bieber , Deshaun Watson , Ashleighj Armstrong , Andrewm Lewis , Hayan Yoon , Jedediah Wakefield , Asaad Hassan , Allergan Inc , Idenix Pharmaceuticals ,

Written Description of Therapeutic Efficacy | Fenwick & West LLP

This article reviews these Federal Circuit decisions and a recent petition for
writ of certiorari.
Idenix v. Gilead
Idenix v. Gilead involved a patent related to a method of treating the hepatitis C virus (HCV) by administering nucleoside compounds. The relevant claim recited:
A method for the treatment of a hepatitis C virus infection, comprising administering
an effective amount
of a purine or pyrimidine β-D-2’-methyl-ribofuranosyl nucleoside or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof.
The “method for the treatment” preamble, in combination with the requirement to administer an “effective amount,” led the U.S. District Court for the District of Delaware to construe the claim to require “use of some set of compounds that are effective for treatment of HCV.” ....

United States , Fenwick West , New Jersey , Eli Lilly , Nuvo Pharmaceuticals , Gilead Sciences , Idenix Pharmaceuticals , Us Court , Us District Court , Supreme Court , Trademark Office , Us Supreme Court , Supreme Court Decided Not To , Ariad Pharmaceuticals , Federal Circuit , Supreme Court Decided Not , ஒன்றுபட்டது மாநிலங்களில் , ஃபென்விக் மேற்கு , புதியது ஜெர்சி , எலி லில்லி , நூவோ மருந்துகள் , கிலியட் அறிவியல் , எங்களுக்கு நீதிமன்றம் , எங்களுக்கு மாவட்டம் நீதிமன்றம் , உச்ச நீதிமன்றம் , முத்திரை அலுவலகம் ,